# US 2015/0147356 A1 · Antipyretics to enhance tolerability of vesicle-based vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147356 A1
- Document ID: US20150147356A1
- Status: Published application
- Kind: A1
- Application number: 14/117,280
- Filed: 2012-05-11
- Published: 2015-05-28
- Earliest claimed: 2011-05-12
- Inventors: Alan Kimura; Peter Dull
- Web page: https://patentgrep.com/patent/US20150147356A1

## CPC

- A61K 39/095: Neisseria
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 38/164: {from bacteria}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for immunising a human subject, wherein the subject receives (i) an immunogenic composition comprising bacterial vesicles and (ii) an antipyretic, and wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other. Paracetamol significantly reduces fever rates without negatively affecting the immunogenicity either of a meningococcal vesicle vaccine or of concomitantly-administered antigens.

## Claims

### Claim 1

A method for immunising a human subject, wherein the subject receives (i) an immunogenic composition comprising bacterial vesicles and (ii) an antipyretic, and wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other.

### Claim 2

An antipyretic and an immunogenic composition comprising bacterial vesicles, for combined use in a method of immunising a human subject, wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other.

### Claim 3

In a method for immunising a human subject by administering an immunogenic composition comprising bacterial vesicles, an improvement consisting of administering an antipyretic to the subject within 24 hours of administering the immunogenic composition.

### Claim 4

A combination of (i) an antipyretic and (ii) an immunogenic composition comprising bacterial vesicles, for simultaneous, separate or sequential administration, wherein components (i) and (ii) are administered within 24 hours of each other.

### Claim 5

A kit comprising (i) an antipyretic and (ii) an immunogenic composition comprising bacterial vesicles.

### Claim 6

A package comprising (i) an immunogenic composition comprising bacterial vesicles and (ii) an information leaflet (a) containing written instructions that an antipyretic may be administered to a subject within 24 hours of their receiving the immunogenic composition and/or (b) instructing a subject or physician to administer an antipyretic to the subject if the subject develops a fever after receiving the immunogenic composition.

### Claim 7

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the antipyretic is administered (i) no more than 2 hours before the immunogenic composition (ii) at the same time as the immunogenic composition or (iii) no more than 2 hours after the immunogenic composition.

### Claim 8

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the subject is less than 1 year old.

### Claim 9

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the vesicles are meningococcal outer membrane vesicles.

### Claim 10 (depends on 9)

The method, composition, improvement, combination, kit or package of claim 9, wherein the vesicles are prepared from a serogroup B meningococcus.

### Claim 11 (depends on 10)

The method, composition, improvement, combination, kit or package of claim 10, wherein the immunogenic composition includes a protein comprising SEQ ID NO: 4, a protein comprising SEQ ID NO: 5, and a protein comprising SEQ ID NO: 6.

### Claim 12 (depends on 10)

The method, composition, improvement, combination, kit or package of claim 10, wherein the vesicles are prepared from a meningococcus in which TbpA expression is upregulated.

### Claim 13 (depends on 10, 12)

The method, composition, improvement, combination, kit or package of claim 10 or claim 12, wherein the vesicles are prepared from a meningococcus in which NhhA expression is upregulated.

### Claim 14 (depends on 10, 12, 13)

The method, composition, improvement, combination, kit or package of claim 10 or claim 12 or claim 13, wherein the vesicles are prepared from a meningococcus in which fHbp expression is upregulated.

### Claim 15 (depends on 10, 12, 13, 14)

The method, composition, improvement, combination, kit or package of claim 10 or claim 12 or claim 13 or claim 14, wherein the vesicles are prepared from a meningococcus in which PorA expression is downregulated.

### Claim 16

A method for immunising a human subject, wherein the subject receives (i) an immunogenic composition comprising a meningococcal fHbp antigen and (ii) an antipyretic, and wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other.

### Claim 17

An antipyretic and an immunogenic composition comprising a meningococcal fHbp antigen, for combined use in a method of immunising a human subject, wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other.

### Claim 18

In a method for immunising a human subject by administering an immunogenic composition comprising a meningococcal fHbp antigen, an improvement consisting of administering an antipyretic to the subject within 24 hours of administering the immunogenic composition.

### Claim 19

A combination of (i) an antipyretic and (ii) an immunogenic composition comprising a meningococcal fHbp antigen, for simultaneous, separate or sequential administration, wherein components (i) and (ii) are administered within 24 hours of each other.

### Claim 20

A kit comprising (i) an antipyretic and (ii) an immunogenic composition comprising a meningococcal fHbp antigen.

### Claim 21

A package comprising (i) an immunogenic composition comprising a meningococcal fHbp antigen and (ii) an information leaflet (a) containing written instructions that an antipyretic may be administered to a subject within 24 hours of their receiving the immunogenic composition and/or (b) instructing a subject or physician to administer an antipyretic to the subject if the subject develops a fever after receiving the immunogenic composition.

### Claim 22 (depends on 16, 17, 18, 19, 20, 21)

The method, composition, improvement, combination, kit or package of any one of claims 16 to 21, wherein the antipyretic is administered (i) no more than 2 hours before the immunogenic composition (ii) at the same time as the immunogenic composition or (iii) no more than 2 hours after the immunogenic composition.

### Claim 23 (depends on 16, 17, 18, 19, 20, 21, 22)

The method, composition, improvement, combination, kit or package of any one of claims 16 to 22, wherein the subject is less than 1 year old.

### Claim 24 (depends on 16, 17, 18, 19, 20, 21, 22, 23)

The method, composition, improvement, combination, kit or package of any one of claims 16 to 23, wherein the immunogenic composition includes a protein comprising SEQ ID NO: 5.

### Claim 25

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the combination of an antipyretic and an immunogenic composition is administered to a subject 2 or more times.

### Claim 26 (depends on 25)

The method, composition, improvement, combination, kit or package of claim 25, wherein the combination of an antipyretic and an immunogenic composition is administered to a subject 3 times.

### Claim 27 (depends on 25, 26)

The method, composition, improvement, combination, kit or package of any one of claims 25 to 26, wherein each administration of the combination in a series is administered within 1 or 2 months of the preceding administration of the combination in the series.

### Claim 28 (depends on 25, 26, 27)

The method, composition, improvement, combination, kit or package of claims 25 to 27, wherein the combination is first administered to a subject at 2 months of age, followed by a second administration of the combination at 3 months of age, and a third administration of the combination at 4 months of age.

### Claim 29

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the immunogenic composition includes an aluminium salt adjuvant.

### Claim 30

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the immunogenic composition is administered by intramuscular injection.

### Claim 31

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the antipyretic is acetaminophen.

### Claim 32

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the antipyretic is administered before the immunogenic composition.

### Claim 33

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the immunogenic composition and the antipyretic are administered within 1 hour of each other.

### Claim 34

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the subject receives the immunogenic composition once and the antipyretic at least twice within a 24 hour period.

### Claim 35 (depends on 34)

The method, composition, improvement, combination, kit or package of claim 34, wherein antipyretic is administered both before and after the immunogenic composition.

### Claim 36

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the antipyretic will be administered orally.

### Claim 37

The method, composition, improvement, combination, kit or package of any preceding claim, wherein the subject also receives an immunogenic composition which does not comprise bacterial vesicles.
